ACR 2019 | The NORD-STAR trial | Conventional versus biologic treatment in early rheumatoid arthritis | Merete Hetland | rheumatology.medicinematters.com

Register Login

Medicine Matters Rheumatology

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

Top

13-11-2019 | Rheumatoid arthritis | Video | Article

Researcher comment: The NORD-STAR trial

Merete Hetland discusses the NORD-STAR trial findings comparing remission rates after active conventional versus biologic treatment in patients with early rheumatoid arthritis (3:52).

Transcript

Medicine Matters Rheumatology

Researcher comment: The NORD-STAR trial

New additions to the Adis Journal Club

Rituximab and rheumatology practice in the COVID-19 era

Related content

Methotrexate plus glucocorticoids compare favorably with biologics in early RA

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

Biologic combination therapy for RA may increase risk for side effects

Treatment tapering in RA: A 2019 update

Medicine Matters Rheumatology

External Content

New additions to the Adis Journal Club

Rituximab and rheumatology practice in the COVID-19 era

Related content

Methotrexate plus glucocorticoids compare favorably with biologics in early RA

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

Biologic combination therapy for RA may increase risk for side effects

​​​​​​​Treatment tapering in RA: A 2019 update

Treatment tapering in RA: A 2019 update